Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma. Issue 6 (19th March 2018)

• Record Type: Journal Article
• Authors: Ho, Nicholas; Peng, Hui; Mayoh, Chelsea; Liu, Pei Y.; Atmadibrata, Bernard; Marshall, Glenn M.; Li, Jinyan; Liu, Tao
• Is Part Of: Cell cycle. Volume 17:Issue 6(2018)
• Page Start: 749
• Page End: 758
• Publication Date: 2018-03-19
• Subjects: Neuroblastoma -- copy number variations -- chromosome gain -- chromosome deletion -- single nucleotide polymorphism array -- survival analysis; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2017.1421875
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Neuroblastoma, the most common solid tumour in early childhood, is characterized by very frequent chromosomal copy number variations (CNVs). While chromosome 2p amplification, 17q gain, 1p and 11q deletion in human neuroblastoma tissues are well-known, the exact frequencies and boundaries of the chromosomal CNVs have not been delineated. We analysed the publicly available single nucleotide polymorphism (SNP) array data which were originally generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, defined the frequencies and boundaries of chromosomes 2p11.2 – 2p25.3 amplification, 17q11.1-17q25.3 gain, 1p13.3-1p36.33 deletion and 11q13.3-11q25 deletion in neuroblastoma tissues, and identified chromosome 7q14.1 (Chr7:38254795-38346971) and chromosome 14q11.2 (Chr14:21637401-22024617) deletion in blood and bone marrow samples from neuroblastoma patients, but not in tumour tissues. Kaplan Meier analysis showed that double deletion of Chr7q14.1 and Chr14q11.2 correlated with poor prognosis in MYCN gene amplified neuroblastoma patients. In conclusion, the oncogenes amplified or gained and tumour suppressor genes deleted within the boundaries of chromosomal CNVs in tumour tissues should be studied for their roles in tumourigenesis and as therapeutic targets. Focal deletions of Chr7q14.1 and Chr14q11.2 together in blood and bone marrow samples from neuroblastoma patients can be used as a marker for poorer prognosis and more aggressive therapies.